Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Edoxaban in Anticoagulant Therapy Early After Surgical Bioprosthetic Valve Replacement: Rationale and Design of the ENBALV Trial

Published:2024-06-24 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Izumi Chisato^ORCID,Amano Masashi,Fukushima Satsuki,Yaku Hitoshi,Eishi Kiyoyuki,Sakaguchi Taichi,Minami Manabu,Yamamoto Haruko,Onda Kaori,Omae Katsuhiro

Funder

Daiichi Sankyo Company

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10557-024-07585-x.pdf

Reference27 articles.

1. Head SJ, Çelik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017;38:2183–91.

2. Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA. 2012;308:2118–25.

3. Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database. J Am Coll Cardiol. 2012;60:971–7.

4. Heras M, Chesebro JH, Fuster V, et al. High Risk of Thromboemboli Early After Bioprosthetic Cardiac Valve Replacement. J Am Coll Cardiol. 1995;25:1111–9.

5. Zhang H, Dong Y, Ao X, Fu B, Dong L; CLIATHVR (Chinese Low Intensity Anticoagulant Therapy After Heart Valve Replacement) multicenter clinical study team. Comparison of antithrombotic strategies in chinese patients in sinus rhythm after bioprosthetic mitral valve replacement: early outcomes from a multicenter registry in China. Cardiovasc Drugs Ther. 2021;35:1–10.